Browsing by Author "Cejalvo, Juan Miguel"

Sort by: Order: Results:

  • AXL - a new player in resistance to HER2 blockade
    Adam-Artigues, Anna; Arenas, Enrique J.; Arribas, Joaquín; Prat, Aleix; Cejalvo, Juan Miguel (Elsevier, 2023)
    HER2 is a driver in solid tumors, mainly breast, oesophageal and gastric cancer, through activation of oncogenic signaling pathways such as PI3K or MAPK. HER2 overexpression associates with aggressive disease and poor ...
  • miR-146a-5p Promotes angiogenesis and confers Trastuzumab Resistance in HER2+ breast cancer
    Cabello, Paula; Torres-Ruiz, Sandra; Adam-Artigues, Anna; Forés-Martos, Jaume; Martínez, María Teresa; Hernando, Cristina; Zazo, Sandra; Madoz-Gúrpide, Juan; Rovira, Ana; Burgués, Octavio; Rojo, Federico; Albanell Mestres, Joan; Lluch, Ana; Bermejo, Begoña; Cejalvo, Juan Miguel; Eroles, Pilar (MDPI, 2023)
    Trastuzumab treatment has significantly improved the prognosis of HER2-positive breast cancer patients. Despite this, resistance to therapy still remains the main clinical challenge. In order to evaluate the implication ...
  • NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer
    Santana-Hernández, Sara; Suárez Olmos, Jesús; Servitja Tormo, Sonia; Berenguer-Molins, Pau; Costa García, Marcel, 1989-; Comerma Blesa, Laura, 1983-; Rea, Anna; Perera Bel, Júlia; Menendez Romero, Silvia; Arpí Llucià, Oriol; Bermejo, Begoña; Martínez, María Teresa; Cejalvo, Juan Miguel; Comino-Méndez, Iñaki; Pascual, Javier; Alba, Emilio; López-Botet, M. (Miguel); Rojo, Federico; Rovira, Ana; Albanell Mestres, Joan; Muntasell i Castellví, Aura, 1972- (BioMed Central, 2024)
    Background: The variability in responses to neoadjuvant treatment with anti-HER2 antibodies prompts to personalized clinical management and the development of innovative treatment strategies. Tumor-infiltrating Natural ...
  • Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial
    Pérez-García, José Manuel; Vaz Batista, Marta; Cortez, Patricia; Ruiz-Borrego, Manuel; Cejalvo, Juan Miguel; de la Haba-Rodríguez, Juan; Garrigós, Laia; Racca,Fabricio; Servitja Tormo, Sonia; Blanch, Salvador; Gion, María; Nave, Monica; Fernández-Abad, María; Martínez-Bueno, Alejandro; Llombart-Cussac, Antonio; Sampayo-Cordero, Miguel; Malfettone, Andrea; Cortés, Javier; Braga, Sofía (Oxford University Press, 2023)
    Background: trastuzumab deruxtecan (T-DXd) has shown durable antitumor activity in pretreated patients with HER2-positive advanced breast cancer (ABC), but its efficacy has not yet been evaluated in patients with active ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking